GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Capex-to-Operating-Cash-Flow

BioPharma Credit (LSE:BPCR) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

BioPharma Credit's Capital Expenditure for the six months ended in Dec. 2022 was $0.00 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2022 was $161.53 Mil.

Hence, BioPharma Credit's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2022 was 0.00.


BioPharma Credit Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for BioPharma Credit's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Capex-to-Operating-Cash-Flow Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

BioPharma Credit Semi-Annual Data
Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioPharma Credit's Capex-to-Operating-Cash-Flow

For the Asset Management subindustry, BioPharma Credit's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPharma Credit's Capex-to-Operating-Cash-Flow Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's Capex-to-Operating-Cash-Flow falls into.



BioPharma Credit Capex-to-Operating-Cash-Flow Calculation

BioPharma Credit's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 123.182
=0.00

BioPharma Credit's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 161.526
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPharma Credit  (LSE:BPCR) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


BioPharma Credit Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPharma Credit (LSE:BPCR) Business Description

Traded in Other Exchanges
N/A
Address
65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ
BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines